Literature DB >> 19368495

Resolvin E1 as a novel agent for the treatment of asthma.

Takeshi Hisada1, Tamotsu Ishizuka, Haruka Aoki, Masatomo Mori.   

Abstract

BACKGROUND: Asthma is characterized by airway hyperresponsiveness and chronic airway inflammation. Inflammatory cells, including eosinophils and lymphocytes, infiltrate peribronchial tissue in patients with asthma. Resolvin E1 (RvE1) is an anti-inflammatory lipid mediator derived from the omega-3 fatty acid, eicosapentaenoic acid, and has been shown to be involved in resolving inflammation. Although little is known about the actions of RvE1 in the resolution of inflammation due to asthma, recent studies in a mouse model have shown the possibilities of RvE1 in asthma. OBJECTIVE/
METHODS: We review the current understanding of the mechanism of RvE1 action in connection with asthma pathogenesis and treatment. RESULTS/
CONCLUSION: Findings provide evidence for the use of RvE1 as a pivotal counter-regulatory signal in allergic inflammation and offer the possibility of novel multi-pronged therapeutic approaches for human asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368495     DOI: 10.1517/14728220902865622

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  10 in total

Review 1.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

Review 2.  New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.

Authors:  Charles N Serhan; Nan Chiang; Jesmond Dalli
Journal:  Mol Aspects Med       Date:  2017-09-01

Review 3.  Resolution of inflammation: a new therapeutic frontier.

Authors:  James N Fullerton; Derek W Gilroy
Journal:  Nat Rev Drug Discov       Date:  2016-03-29       Impact factor: 84.694

4.  Are specialized pro-resolving mediators promising therapeutic agents for severe bronchial asthma?

Authors:  Takeshi Hisada; Haruka Aoki-Saito; Yasuhiko Koga
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  Paradigm shift - Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery.

Authors:  Ganesh V Halade; Laurence M Black; Mahendra Kumar Verma
Journal:  Biotechnol Adv       Date:  2018-02-28       Impact factor: 14.227

Review 6.  Molecular Pharmacology of Inflammation Resolution in Atherosclerosis.

Authors:  Stanislav Kotlyarov; Anna Kotlyarova
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

7.  Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes.

Authors:  Bruno S Herrera; Hatice Hasturk; Alpdogan Kantarci; Marcelo O Freire; Olivia Nguyen; Shevali Kansal; Thomas E Van Dyke
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

8.  Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing.

Authors:  Miguel Quiros; Darius Feier; Dorothee Birkl; Rachit Agarwal; Dennis W Zhou; Andrés J García; Charles A Parkos; Asma Nusrat
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-16       Impact factor: 12.779

Review 9.  Omega-3 Fatty Acids in Modern Parenteral Nutrition: A Review of the Current Evidence.

Authors:  Stanislaw Klek
Journal:  J Clin Med       Date:  2016-03-07       Impact factor: 4.241

Review 10.  Lipid-Derived Mediators are Pivotal to Leukocyte and Lung Cell Responses in Sepsis and ARDS.

Authors:  Julie Nijmeh; Bruce D Levy
Journal:  Cell Biochem Biophys       Date:  2021-06-27       Impact factor: 2.194

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.